Connection

Jean-Charles Soria to Disease Progression

Back to Details
This is a "connection" page, showing publications Jean-Charles Soria has written about Disease Progression.
Jean-Charles Soria
Connection Strength
0.288
Disease Progression
  1. Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. Eur J Cancer. 2017 11; 85:155-157.
    View in: PubMed
    Score: 0.180
  2. Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines? Br J Cancer. 2018 10; 119(8):937-939.
    View in: PubMed
    Score: 0.049
  3. Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol. 2018 12; 15(12):748-762.
    View in: PubMed
    Score: 0.012
  4. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression. Eur J Cancer. 2018 09; 101:160-164.
    View in: PubMed
    Score: 0.012
  5. Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. Eur J Cancer. 2018 05; 95:68-74.
    View in: PubMed
    Score: 0.012
  6. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2018 Mar 01; 4(3):351-357.
    View in: PubMed
    Score: 0.012
  7. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018 01; 88:38-47.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.